Myrexis, Inc. (Formerly Known as Myriad Pharmaceuticals, Inc.) Reports Second Quarter Fiscal 2011 Financial Results

SALT LAKE CITY, Feb. 9, 2011 (GLOBE NEWSWIRE) -- Myrexis, Inc. (Nasdaq:MYRX), a biotechnology company focused on discovering, developing, and commercializing novel treatments for cancer, today reported financial results for its second fiscal quarter ended December 31, 2010. The Company ended the quarter with $132.8 million in cash, cash equivalents and marketable securities. During the quarter the Company received grants of approximately $1.2 million under the Internal Revenue Code Section 48D for Qualifying Therapeutic Discovery Projects.